Autophagy is a cellular quality control and energy-providing process that is under strict control by intra-and extracellular stimuli. Recently, there has been an exponential increase in autophagy research and its implications for mammalian physiology. Autophagy deregulation is now being implicated in many human diseases, and its modulation has shown promising results in several preclinical studies. However, despite the initial discovery of autophagy as a hormone-regulated process by De Duve in the early 1960s, endocrine regulation of autophagy still remains poorly understood. In this review, we provide a critical summary of our present understanding of the basic mechanism of autophagy, its regulation by endocrine hormones, and its contribution to endocrine and metabolic homeostasis under physiological and pathological settings. Understanding the cross-regulation of hormones and autophagy on endocrine cell signaling and function will provide new insight into mammalian physiology as well as promote the development of new therapeutic strategies involving modulation of autophagy in endocrine and metabolic disorders. (Endocrine Reviews 38: 2017) 
T he term autophagy was first used 50 years ago by Christian De Duve, who received the Nobel Prize for his discovery of the lysosome. Indeed, his early seminal work on autophagy was based upon glucagon-stimulated autophagy in the rat liver (1) . Autophagosomes later were shown to contain remnants of cell organelles, and their number could be induced by starvation. The composition and regulation of autophagosomes remained poorly understood until Yoshinori Ohsumi and his colleagues identified proteins that comprised the autophagosome in yeast in the 1990s (2) , for which he was awarded the Nobel Prize in 2016. Since then, there has been a surge of interest in this field, although its relevance to endocrine systems has only recently been reexamined, despite the early work of De Duve. Here, we provide a comprehensive overview of the latest research developments on autophagy in endocrine/metabolic signaling in health and disease.
II. Types and Features of Autophagy
Macroautophagy, microautophagy, chaperonemediated autophagy, and crinophagy
Macroautophagy
Macroautophagy [referred to as autophagy hereafter, unless otherwise specified; Fig. 1(A) ] is one of the best understood types of autophagic processes and involves the sequestration of cytosolic substrates within cytosolic double-membrane vesicles termed autophagosomes (3) . The substrates of autophagy are diverse and include cytosolic proteins, glycogen, lipids, nucleic acids, damaged organelles, and invasive microbes. Following their degradation, the breakdown products are released back into the cytosol and can be recycled into the macromolecular constituents, generate energy to maintain cell viability under unfavorable conditions, or confer protection/survival during cellular distress (3) . Macroautophagy and microautophagy are multistep processes that share similar proteins. Under upstream signaling cascades, formation of initial sequestering structure occurs and phagophore forms, which then undergoes a series of further membrane expansion and elongation events to yield a completed double-membrane sequestering vesicle, or autophagosome. During autophagosome formation, diverse substrates (cytosolic proteins, glycogen, lipids, nucleic acids, damaged organelles, and invasive microbes, also known as cargo) of autophagy (for non-selective/general autophagy) or selected substrate (for selective autophagy) come into autophagosomal vesicle. Later, these autophagosomes or amphisome (autophagosome fused with endosome in mammalian cells) fuse with lysosome to form an autolysosme, where doi: 10.1210/er.2016-1103 press.endocrine.org/journal/edrv 71
The initial sequestering structure is termed the phagophore (4) . The origin and nucleation of the phagophore is still not well understood; currently, ER-mitochondria contact sites have been proposed to provide the priming membrane for phagophore formation (5) . Phagophores serve as "autophagosomal precursors" that undergo a series of further membrane expansion events to yield a completed double-membrane sequestering vesicle, or autophagosome, for autophagy (4) .
After its formation and engulfment of cellular cargos, the autophagosome fuses with a lysosome/vacuole. In mammalian cells, the autophagosome may first fuse with an endosome to generate an amphisome, which then fuses with a lysosome. The cellular component resulting from autophagosome/amphisome fusion with a lysosome is termed an autolysosome. Within the autolysosome, there is lysis of the autophagosome inner membrane, followed by breakdown of the cargo through the action of lysosomal/vacuolar hydrolases and the release of the degradation products via membrane permeases (6) (7) (8) (9) .
Derangement in the macroautophagic pathways has been implicated in many human diseases (10) , and its impact on endocrinology and metabolism will be discussed in this review in greater detail. The subclassification of macroautophagy and its mechanistic details will be further elucidated in the next sections.
Microautophagy Microautophagy [ Fig. 1(A) ] is a lysosomal degradative process that involves direct engulfment of cytoplasmic cargo by the lysosomal membrane (11) (12) (13) . Microautophagy is especially important for the survival of cells during starvation or nitrogen deprivation, or after rapamycin treatment (14) . Microautophagy generally is a nonselective process in mammals, but there are at least 3 examples of selective microautophagic pathways that are activated under specific conditions in yeast (12) .
At a mechanistic level, the microautophagic process starts with membrane invagination and autophagic tube formation at the surface of the lysosomal membrane. This stage is followed by vesicle formation, expansion, and scission from the autophagic tube, leading to transfer into the lysosome. The microautophagic vesicle and its cargo are then degraded via hydrolases in the lysosomal lumen (15) . In mammalian cells, microautophagy can sequester cytosolic components during the biogenesis of multivesicular bodies/late endosomes (MVBs) (16, 17) , or directly by engulfment of intracellular constituents at the lysosomal membrane. The docking and fusion step is tightly linked to the microautophagy of MVB, and blockage of this process has been observed in Alzheimer's (18) , Creutzfeldt-Jakob (19) , Gerstmann-StrausslerScheinker (20) , and glycogen storage diseases (21).
Chaperone-mediated autophagy
Chaperone-mediated autophagy [CMA; Fig. 1(A) ] is a highly selective autophagic process in which proteins are targeted for lysosomal degradation via chaperone proteins (22, 23). Proteins that undergo degradation by CMA are selected individually by the presence of a recognition motif in their amino acid sequences (24). The specificity of CMA enables the removal of specific proteins and makes CMA an efficient system to degrade damaged or abnormal proteins, as well as surplus subunits of multiprotein complexes. In addition, this selectivity allows CMA to play a regulatory role in multiple cellular processes that can modulate intracellular levels of various enzymes, transcription factors, and cell maintenance proteins (22). . these cargos are digested by lysosomal hydrolases. Unlike microautophagy, which does not require autophagosome formation, macroautophagy is a lysosomal degradative process that involves direct engulfment of cytoplasmic cargo by the lysosomal membrane. CMA is a highly selective autophagic process in which proteins are targeted for lysosomal degradation via chaperone proteins. Proteins that undergo degradation by CMA are selected individually by the presence of a penta-peptide amino acid recognition KFERQ motif recognized by cytosolic chaperone, a 70-kDa heat shock protein (hsc70) that targets the substrate protein to the lysosome surface. This substrate protein-chaperone complex then binds to LAMP-2A. Later, substrate proteins are translocated and subsequently degraded rapidly by multimerized LAMP-2A, along with other chaperone proteins (Hsp90) located at the lysosomal membrane. Crinophagy is a highly selective type of autophagy that occurs in some endocrine tissues (e.g., pituitary, pancreatic islets) in which secretory granules containing cell-specific proteins/peptide hormone such as prolactin, insulin, etc., that are intended for secretion, instead are fused directly with lysosomes, and subsequently degraded. (B) Autophagy signaling cascade. Autophagy is initiated by the formation of phagophores in the cytoplasm. (i) Initiation: Typically, mTORC1 regulates autophagy by inhibiting the ULK1 complex (ULK1-ATG13-FIP200) that is necessary for the induction of the autophagy pathway. Calcium-dependent activation of AMPK by CaMKKb activates the ULK1 complex that initiates the autophagy pathway. However, mTOR-independent pathways regulating autophagy are not very clear. The complex comprising hVps34, Beclin-1 (BECN1), and hVps15 regulates autophagosome synthesis, possibly downstream of the mTOR-independent pathways. Several BECN1 interactors, such as ATG14L, UV Radiation Resistance Associated (UVRAG), and Autophagy And Beclin 1 Regulator 1 (AMBRA1), or Rab5 interacting with hVps34, positively modulate this process. (ii) Phagophore elongation: Two ubiquitinlike conjugation systems involving ATGs regulate elongation of phagophores. The ATG5-ATG12 conjugation involves ATG (E1-like) and ATG10 (E2-like), whereas the light chain 3 (LC3)-LC3-I-phosphatidylethanolamine (PE) conjugation involves ATG4 (cysteine protease), ATG7 (E1-like), and ATG3 (E2-like). The ATG5-ATG12 conjugate forms a complex with ATG16, which has E3-like activity toward LC3-I-PE conjugation (LC3-II). (iii) Autophagosome: Upon autophagosome closure, sealing the typical double membrane organelle, ATG5-ATG12/16 dissociate from the outer autophagosomal membrane and are recycled. (iv) Autolysosme: Autophagosome maturation involving fusions with late endosomes and lysosomes are mediated by Rab7, endosomal sorting complexes required for transport (ESCRT) proteins, soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) proteins, and the UVRAG-BECN1-hVps34-hVps15 complex. Autophagic cargo consisting of nonspecific or specific substrates [as shown in Fig. 1(A) ] are degraded in the autolysosomes.
CMA substrate proteins have a penta-peptide amino acid recognition motif that is biochemically related to KFERQ as amino acid sequence (25). This CMA-targeting motif is recognized by a cytosolic chaperone, a 70-kDa heat shock cognate protein (hsc70), to target the substrate to the lysosome surface (26). This substrate proteinchaperone complex then binds to lysosome-associated membrane protein type 2A (LAMP-2A), which acts as the receptor for this pathway (27). Upon protein substrate binding, monomers of LAMP-2A trigger the assembly of LAMP-2A multimers with the help of other chaperone proteins such as heat shock protein 90 (Hsp90), hsc70, and cochaperones located at the lysosomal membrane (28). The substrate proteins are subsequently rapidly degraded by the lysosomal proteases after translocation (29).
CMA contributes to the maintenance of cellular homeostasis by facilitating the recycling of amino acids of the degraded proteins (contributing to cellular energy balance) and by removing abnormal or damaged proteins (contributing to cellular quality control). Several human diseases such as age-related neurodegeneration, cancer, and lipid disorders have been associated with defects in CMA, and presently, it is a novel therapeutic target for the treatment of several metabolic and neurodegenerative disorders (22).
Crinophagy Crinophagy [ Fig. 1(A) ], was first discovered in pituitary mammotrophs (30) and derives its name from the Greek word "crin," which means "to secrete." It is a highly selective type of autophagy in which the secretory granules of some endocrine tissues (e.g., pituitary, pancreatic islets) that contain cell-specific proteins such as prolactin, insulin, etc. (31, 32), are fused directly with lysosomes and are subsequently degraded. There is evidence that crinophagy exists in peptide-secreting endocrine tissues and may be the main pathway for degrading excess secretory material (33). Crinophagy is stimulated in response to an inhibition of secretion or an overproduction of secretory material, but the mechanism(s) of its induction and regulation remains largely unknown (34). Also, it is not known whether crinophagy shares protein components and/or signaling pathways with those involved in macroautophagy. Because crinophagy fine-tunes hormone content and secretion based upon varying physiological states, its pathological disturbance can result in hormonal hypo-or hypersecretion.
Autophagy-related genes
In 1993, the Ohsumi laboratory (2) reported the isolation and characterization of 15 S. cerevisiae mutants that displayed impaired autophagy and named them apg1-15 (autophagy). Concurrently, Harding et al. (35) also identified mutants defective in either autophagy or the cytoplasm-to-vacuole pathway. Following these initial discoveries, a unified nomenclature for the so-called autophagy-related genes/proteins, Atgs, was proposed (36). Functionally, mammalian ATGs can be subdivided into 6 functional protein clusters: (1) the Unc-51-like autophagy activating kinase 1 (ULK1)-ATG13-200 kDa FAK family kinase-interacting protein (FIP200)-ATG101 protein kinase complex; (2) the Phosphatidylinositol 3-kinase (PtdIns3K) class III complex containing the core proteins VPS34, VPS15, and Beclin 1; (3) the PtdIns3P-binding WD repeat domain phosphoinositide-interacting protein 1(WIPI)/ATG18-ATG2 complex; (4) the multispanning transmembrane protein ATG9A; (5) the ubiquitinlike ATG5/ATG12 system, and (6) the ubiquitinlike ATG8/light chain protein 3 (LC3) conjugation system (4, 37). These 6 clusters regulate various steps during autophagosome biogenesis, e.g., vesicle nucleation, phagophore formation, expansion of the autophagosomal membrane, autophagosome completion, and autophagosome/lysosome fusion. The cascade of autophagy progression involving contribution of different ATGs is shown in Fig. 1 
(B) .

Posttranslational regulation of autophagy
Posttranslational regulation (Fig. 2) is essential for the rapid induction of autophagy in response to different types of environmental stress, and the fine-tuning of the amplitude and duration of autophagic flux. Posttranslational modifications can be classified into 3 broad categories: phosphorylation, ubiquitination, and acetylation (38-41).
Phosphorylation
Phosphorylation of ATG proteins is the most well understood posttranslational modification. Phosphorylation of ATG proteins either regulates the biological activity of the protein or its interaction with binding partners. In this regard, ULK1/ATG1 is one of the most common phosphorylation targets to regulate autophagy (42). ULK1 activity serves as an essential initial step for autophagosome formation and is under the strict control of upstream energy/nutrient sensing kinases, 5 0 adenosine monophosphate-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) (43). AMPK directly activates ULK1 via phosphorylation to initiate autophagy induction during low-energy states such as starvation. In contrast, mTORC1 inhibits ULK1 by phosphorylating it at another site during nutrient-rich conditions. Because ULK1 is a kinase, it also can relay the autophagic signal by phosphorylating other ATG proteins such as ATG13 (44) 
Ubiquitination
Ubiquitination either can affect the stability of Atg proteins or serve as a signal to recruit autophagy receptors (50). Phosphatase and tensin homolog-induced putative kinase 1 is a serine/threonine kinase that binds to depolarized mitochondria and recruits PARK2/parkin (parkin RBR E3 ubiquitin protein ligase), an E3 ligase that catalyzes ubiquitination of mitochondrial substrates to promote mitochondrial recognition during early autophagosome formation. This process, termed mitophagy, and the concomitant mitochondrial biogenesis, are important for renewal and maintenance of mitochondrial quality as well as mitochondrial homeostasis (51). Interestingly, although ubiquitination of ULK1/ATG1 (52) and Beclin/ATG6 (53) promote their stability, ubiquitination of ATG4B promotes its degradation (54).
Acetylation
ATG proteins also are regulated directly by acetylation (55). During serum starvation, the K(lysine) acetyltransferase 5 directly acetylates ULK1, which leads to ULK1 activation and autophagy initiation (56). In contrast, acetylation of ATG proteins by E1A binding protein p300 inhibits autophagy (57). Likewise, deacetylases such as sirtuins act in a complementary manner and Transcriptional regulation occurs through various nuclear transcription factors [FOXOs, P53, nuclear factor-kB (NF-kB), TFEB, CREB, zinc finger with KRAB and SCAN domains, E2F1, Ume6, and ATF4] and nuclear hormone receptors (PPARs, VDRs, ERs, FXRs, and TRs) that induce expression of autophagy (ATG) genes in mammalian cells. Epigenetic changes such as histone acetylation/methylation modifications during prolonged stress also occur, which regulate transcription of ATG genes. Translational regulation of autophagy gene transcripts can be mediated by microRNAs and RNA binding proteins such as BCL2-associated athanogene 3 (BAG3). Posttranslational modification of ATG proteins happens rapidly to regulate autophagic flux during various cellular and environmental stress periods. Acetylation is regulated by acetyltransferase [K(lysine) acetyltransferase 5 (KAT5/TIP60)] and deacetylases (such as SIRT1) that act in a complementary manner on ATG proteins. KAT5 acetylates ULK1 and activates the autophagy process, whereas E1A binding protein p300 (EP300) acetylates various ATG proteins to inhibit autophagy. HDAC6 deacetylates cortactin, whereas SIRT1 deacetylates various ATG proteins and induces autophagy. Phosphorylation of ATG proteins is the most well understood posttranslational modification. ULK1 (an important protein in autophagy), along with its activity, serves as an essential initial step for autophagosome formation, and thus is under the strict control of upstream energy/nutrient sensing kinases, AMPK and mTORC1. AMPK and mTOR phosphorylate ULK1 to activate or deactivate it respectively. ULK1 also phosphorylates other ATG proteins and regulates autophagosome formation. Ubiquitination can either affect the stability of ATG proteins or serve as a signal to recruit autophagy receptors. E1 (ubiquitin-activating enzyme), E2 (ubiquitinconjugating enzyme), and E3 (ubiquitin ligase) regulate mono/poly ubiquitination of various ATG proteins to regulate their stability. Parkin (an E3 ligase) ubiquitinates Voltage-dependent anion channel (VDAC) on the mitochondrial outer membrane and serves as a receptor for damaged mitochondria in the authophagosome by interacting with LC3 (using the LC3-interacting region domain). Other protein modifications, such as glycosylation of Beclin1 by O-GlcNAc transferase (OGT) via a less understood mechanism inhibits autophagy, whereas prenylation of ATG proteins by small guanosine triphosphatase (also through its own prenylation during mevalonate pathway) activates autophagy.
activate ATG proteins to induce autophagy (58). Besides these modifications, glycosylation (59) and prenylation (60) of ATG proteins are involved in the regulation of autophagy and modulation of autophagic flux in cells.
Transcriptional regulation of autophagy
Autophagy initially was considered an exclusively cytoplasmic process that was regulated by a set of rapid protein modification events and thus did not require de novo transcription or translation (61). This view has been slowly changing, particularly for sustained autophagy, because we subsequently have learned that nuclear transcription factors also can play critical roles in promoting autophagic flux in cells (39, 62, 63) . At the transcriptional level ( Fig. 2) , nuclear transcription factors such as forkhead box O proteins (FOXO) 1/3, P53, nuclear factor-kB, transcription factor EB (TFEB), cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), zinc finger with KRAB and SCAN domains 3, E2F transcription factor 1 (E2F1), Ume6, and ATF4 induce autophagy by regulating the promoter activity and expression of ATG genes (64) (65) (66) (67) (68) (69) . Similarly, nuclear hormone receptors such as peroxisome proliferator-activated receptors (PPARs), vitamin D receptors (VDRs), estrogen receptors (ERs), farnesoid X receptors (FXRs), and thyroid hormone (TH) receptors recently have been shown to modulate autophagy gene expression in mammalian cells (70) (71) (72) (73) (74) (75) . Transcription of ATG genes also can be influenced by epigenetic changes such as histone acetylation modifications (76) during prolonged stress and the establishment of autophagy "memory" (77) . Besides transcription, posttranscriptional regulation of autophagy gene transcripts (Fig. 2 ) also can be mediated by microRNAs and RNA binding proteins such as B-cell lymphoma 2 (BCL2)-associated athanogene 3 (78) (79) (80) .
Selective vs nonselective autophagy
Autophagy initially was described as a nonselective bulk process induced in response to starvation and other stresses. However, in recent years, it has become clear that the turnover of damaged organelles, removal of protein aggregates, and elimination of intracellular pathogens are highly selective and tightly regulated processes that require precise cargo recognition by the autophagy machinery (81, 82) . Different cargos of selective autophagy (Fig. 1 ) have been described, such as aggregated proteins (aggrephagy), lipids (lipophagy), mitochondria (mitophagy), peroxisomes (pexophagy), ribosomes (ribophagy), endoplasmic reticulum (reticulophagy), and pathogens (xenophagy). Selectivity is achieved through specific autophagy receptors that recognize cargos tagged with degradation signals as well as bind to the autophagosomal membrane via their LC3-interacting regions (81, 83) . In general, the LC3-interacting region motifs interact with autophagy modifier proteins of the LC3/Gamma-aminobutyric acid receptor-associated protein (GABARAP) family located on the autophagosome outer membrane. Some of the best characterized autophagy receptors are BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (NIX), FUN14 domain containing 1 for mitophagy (FUNDC1), Calcium binding and coiled-coil domain 2 (NDP52), optineurin for xenophagy, neighbor of breast cancer 1 gene 1 (NBR1) for pexophagy, and NBR1, histone deacetylase 6 (HDAC6), BCL2-associated athanogene 3 (BAG3) for aggrephagy. Sequestosome-1 (SQSTM1/p62) appears to be involved in each of these types of autophagy (81, 83) .
Molecular tools to study autophagy
The different stages of autophagy such as autophagosome formation, cargo selection/specificity, autolysosome formation, and net autophagic flux can be monitored by specific assays. One of the best characterized methods to assess autophagosome formation is the measurement of microtubule-associated LC3/ATG8 lipidation. LC3 is lipidated and localized in the autophagosome membrane; therefore, it can monitor both endogenous and/or ectopically expressed LC3. Immunofluorescent puncta formation in cells and quantification of LC3-II (lipidated) by Western blotting are also useful to estimate the amount of autophagy. Historically, electron microscopy has been a gold standard to visualize autophagy; however, because it is a static measurement like the previous methods, it cannot determine autophagic flux in a cell system without additional molecular assays. Thus, although the foregoing methods can assess the accumulation of autophagosomes, they cannot distinghish between activation of autophagy and a block in autophagosome turnover. The evaluation of autophagic flux often is necessary for proper evaluation of the autophagic state in cells. One indicator of autophagic flux is a decrease in SQSTM1/p62, presumably because of lysosomal degradation. SQSTM1/p62 is a cargo adapter protein for autophagic degradation of protein aggregates and organelles; thus, its protein expression can reflect the relative protein degradation that occurs when there is unimpeded autophagy. Similarly, lysosomal function can be measured using pH-sensitive dyes/fluorophores, such as acridine orange, monodansylcadavarin, and lysotracker. Another frequently used method to evaluate autophagic flux is to detect further accumulation of LC3-II after the addition of lysosomal inhibitors. The employment of pH-sensitive dual flurophore-tagged LC3 plasmid is another good way to assess autophagic flux. Duallabeling of different subcellular organelles or proteins with LC3 or lysosomal markers is yet another commonly used method to assess selective autophagy. Detailed guidelines for the use of different autophagy assays and their interpretation have been described by Klionsky et al. (84) .
III. Hormonal Regulation of Autophagy
The regulation of autophagy and metabolism in higher organisms is more complex than in unicellular ones. First, there is a need to maintain overall viability and health of the organism by regulating metabolic processes in multiple tissues. Second, the metabolic needs may vary according to the particular fuels used by different tissues. For instance, in the fasted state, the brain utilizes glucose and ketones to form adenosine triphosphate (ATP), whereas the liver utilizes fatty acids to generate ketones and ATP. The ATP is then used to support gluconeogenesis by the liver, so that glucose can be exported and used by the brain. Thus, individual organs must not only be able to sense their own energy state, but also the needs of the entire organism, and then respond accordingly.
In higher eukaryotes, the endocrine system mediates the intercellular coordination and communication among different tissues that are necessary to serve the metabolic needs of the whole organism. Accordingly, hormones are synthesized and released by endocrine glands to communicate and control the actions of their target tissues. The endocrine glands themselves are often hormone regulated and also subject to negative feedback control by increased levels of their secreted hormone or other downstream signals. In target tissues, hormones bind to specific receptors that are usually located on the plasma membrane or in the nucleus. Typically, polypeptide hormones bind to plasma membrane receptors, whereas small molecules such as steroid hormones and THs bind to nuclear receptors.
Hormone signaling is a specific yet complex means for conveying information about the energy state of the entire organism to the target tissue, where it is interpreted and integrated to generate appropriate responses that are important for the maintenance and survival of the whole organism. Thus, it is not surprising that hormones have key roles in regulating many metabolic processes and functions in the cell through the activation or inhibition of metabolic pathways, and the expression of genes involved in those pathways. There is now increasing evidence that autophagy is among those cellular metabolic processes that are regulated by hormones. Moreover, because autophagy is regulated simultaneously in many tissues at the level of the whole organism, the amount of autophagy in any given tissue in vivo will depend upon the integration of both intracellular and endocrine signals. Furthermore, given the broad range of signals and cellular functions for autophagy, it is not surprising that there have been discrepant observations made by various groups. These may be due, in part, to different genetic models, dietary conditions, levels of autophagy inhibition, the autophagy-independent action of some autophagy proteins, or experimental conditions such as the age and sex of the mice used in the studies. This review will focus mainly on the hormonal regulation of autophagy in mammals; however, there has been much work on the endocrine regulation of autophagy in invertebrates, which has been well described elsewhere (85, 86) .
Following is a brief summary of regulation of autophagy by individual mammalian hormones and their receptors.
Glucagon
Glucagon is a polypeptide hormone that is secreted during the fasting state and acts on target tissues, particularly the liver, to promote lipid catabolism and gluconeogenesis (87) . It also acts upon adipose, kidney, gut, brain and heart tissue to facilitate their intracellular adaptations to the fasting state (87) . Glucagon binds to a plasma membrane-bound G protein-coupled receptor (GPCR), the glucagon receptor, and activates the cAMP/ protein kinase A (PKA) signaling axis (88) . The glucagon receptor also can stimulate the phospholipase C/inositol triphosphate pathway to increase intracellular Ca 2+ levels (88) . Additionally, intracellular cAMP can activate alternative metabolic pathways that are mediated by exchange proteins activated by cAMP (Epacs) to stimulate Sirtuin 1 (SIRT1) and AMPK (89, 90) . The first demonstration of endocrine regulation of autophagy was made in the 1960s by De Duve et al. (91), who showed that the classical counter-regulatory hormone, glucagon, stimulated autophagy in the rat liver. Soon afterward, autophagy was found to be induced by glucagon in a cell-autonomous manner in cultured hepatocytes (92) and dependent upon an increase in intracellular cAMP in these systems (92, 93) . However, cAMP later was found to inhibit autophagy in isolated hepatocytes (94) ; therefore, its action on autophagy remained controversial for many years. More recent work has suggested that cAMP can induce autophagy, most likely through the classical PKA signaling pathway (95) , although it is possible that pathways involving Epac (96) or extracellular signal-regulated kinase (ERK) (97) also may be involved. Because autophagy can be regulated by both hormone and nutrient levels, and can depend upon specific cell type, it is likely that some of the apparently conflicting findings reported by different groups may be due to their employment of different experimental systems.
The physiological role of glucagon induction of autophagy is not well understood. Although glucagon was previously known to promote glycogen breakdown by the classical glycogen phosphorylase pathway (88) , it was found to induce autophagy necessary for hepatic glycogen breakdown in newborn rats (98) . In the latter situation, autophagy may have served as a more rapid method to degrade large amounts of glycogen, especially because there is a strong need for rapid supply of glucose during the postnatal period (99) . Although other hormones have been shown to induce autophagy to degrade lipids (lipophagy) in the liver (100), it is not known whether glucagon promotes this effect when it stimulates b-oxidation of fatty acids. Besides glucagon, glucagon like peptide-1 has also been shown to induce autophagy in liver cells (101) (102) (103) .
Insulin and insulin-like hormones
Insulin is synthesized by islet b-cells in the pancreas. It is released when there is an increase in glucose concentration, and stimulates anabolic metabolism within the entire organism (104) , particularly in adipose tissue, muscle, and liver. Besides stimulating glucose uptake in target tissues after feeding, insulin also promotes lipogenesis, cell growth, and cell survival (104) . Insulin acts by binding to its plasma membrane-bound receptor, a tyrosine kinase that is autophosphorylated upon insulin binding, and activates the insulin receptor substrates (IRS) 1 or IRS2. These events eventually lead to the downstream phosphorylation and activation of AKT (also known as protein kinase B) (105) . AKT then phosphorylates and inactivates Tuberous sclerosis 1 (TSC1), which is a negative regulator of mTORC1 (106) . AKT also phosphorylates and inhibits the nuclear translocation of FOXO proteins, a family of transcription factors that stimulate the expression of autophagy genes (107) . In addition, mTORC1 can phosphorylate and inhibit the nuclear translocation of TFEB, a transcription factor involved in the regulation of autophagy and lysosomal target genes. Insulin likely inhibits autophagy acutely through mTORC1 phosphorylation and inhibition of ULK1, whereas it inhibits autophagy chronically by decreasing the transcription of FOXO-regulated autophagy genes (107) .
Given that some of the key cellular signaling pathways that regulate autophagy are inhibited by insulin, it might be expected that insulin inhibits autophagy. However, it initially was difficult to distinguish between the lack of insulin and the accompanying rise in glucagon commonly observed in in vivo diabetes models (108) . Later studies eventually determined that insulin inhibited autophagy in the liver (109, 110), muscle (111) , and brain (112) . Moreover, deletion of IRS1/2 in the heart abrogated insulin signaling in the heart and strongly induced autophagy (113) . However, insulin's effects on autophagy ultimately may depend upon tissue type and nutrient availability, given that insulin strongly inhibited autophagy in skeletal muscle but had no effect on the liver when serum levels of glucose and amino acids were clamped (111) . Instead, the primary signal for inhibition of hepatic autophagy after feeding was a rise in serum free amino acids (111) .
Insulin-like growth factor 1 (IGF-1) binds to a transmembrane tyrosine kinase receptor that shares homology with the insulin receptor (IR). The ligandbound receptor activates cell signaling pathways that overlap those of the IR, and mimics some of insulin's intracellular effects. Additionally, both insulin and IGF-1 have amino acid and structural homology as well as lowaffinity crossreactivity with each other's receptors. Deletion of IRs from cardiac cells did not increase autophagy as much as expected, because it was likely that insulin action was partially maintained via insulin binding to, and activation of, the IGF-1 receptor (IGF-1R) (114) . Additionally, IGF-1 binding to its own receptor inhibits autophagy through activation of the classical AKT signaling pathway (115) .
Catecholamines
Catecholamines are derived from tyrosine and can act either as hormones or neurotransmitters. There are 3 major catecholamines that play prominent physiological roles: epinephrine (adrenaline), norepinephrine (noradrenaline), and dopamine (116) . Epinephrine and norepinephrine act as neurotransmitters for both the central and the peripheral sympathetic nervous systems (116) . They are synthesized in the adrenal medulla, and can have effects on the blood vessels, adipose tissue, brain, heart, liver, kidney, and smooth muscle when released into the circulation. Dopamine is a neurotransmitter (116) that is synthesized by the adrenal gland and kidney (117) . Its primary peripheral targets are the vascular system, heart, and kidney. The receptors for all 3 catecholamines are GPCRs. Dopamine has its own set of 5 receptors (117) whereas norepinephrine and epinephrine share a common set of 5 receptors, termed the adrenergic receptors, that can be subdivided into 2 categories, a and b receptors, based upon their ligand affinity properties (118) . The adrenergic receptors differ in their tissue distribution (119, 120) and their relative affinity for epinephrine or norepinephrine (121, 122) . Adrenergic receptors are GPCR kinases that typically increase cAMP signaling in a manner similar to that of glucagon (123) . Additionally, ligand binding to adrenergic receptors leads to b-arrestin binding to the receptor, an event that blocks further G protein-coupled signaling, press.endocrine.org/journal/edrv 77 and targets the receptor for internalization. b-arrestin binding to the receptor also serves as a scaffold for activating other signaling pathways, such as those mediated by c-src and ERK1/2 (124). Epinephrine and norepinephrine secretion by the adrenal gland increases during starvation (125) (126) (127) ; thus, it might be expected that they would regulate autophagy in response to stress. Indeed, treatment of newborn rats with epinephrine increased glycogen degradation by autophagy in hepatocytes and cardiomyocytes (98) . In mice deficient in epinephrine, hepatic levels of the key autophagic protein, ATG5, also were decreased (128) . Furthermore, we observed autophagic flux in hepatocytes and liver that could be stimulated by epinephrine and clenbuterol, and blocked by propranolol (129) . Interestingly, epinephrine was able to induce autophagy 1 hour after treatment, consistent with its role as a stress hormone. Although it still remains to be demonstrated definitively, it is likely that these effects on autophagy by b-adrenergic agonists also promote fatty acid oxidation and gluconeogenesis during starvation and other stressrelated states.
b-adrenergic stimulation of white adipose tissue increases lipolysis via PKA-mediated activation of hormone-sensitive lipase (130) . However, this may not be the only mechanism for lipolysis, given that b-adrenergic stimulation also induces autophagy of lipid droplets to facilitate the transport of triglycerides into lysosomes for hydrolysis (130, 131) . In skeletal muscle, adrenergic signaling represses autophagy-mediated proteolysis (130) and thus could be an adaptative response by the organism to conserve muscle mass during starvation or in stressful fight-or-flight situations. In the heart, b 2 -adrenergic signaling increases fibroblast autophagy and reduces collagen deposition (132) . Activation of the a1 receptors and inhibition of b 1 receptors by autoantibodies increase and inhibit autophagy, respectively (133, 134) . In contrast, b 2 -adrenergic signaling inhibits autophagy-mediated proteolysis in the heart (135). Thus, the differing effects of adrenergic signaling on cardiac autophagy are complex, and may depend upon the experimental conditions or animal model system examined. In contrast with norepinephrine and epinephrine, dopamine selectively regulates autophagy in neurons (136) (137) (138) (139) . Thus far, there have not been any reports on systemic dopamine regulation of autophagy in peripheral target tissues.
Nuclear hormone receptors
Nuclear hormone receptors (NRs) are ligand-activated transcription factors that regulate gene expression by interacting with specific DNA sequences upstream of their target genes (140) . They comprise an ancient phylogenetic family of proteins (48 in humans) that can bind to small ligands, such as steroid and thyroid hormones, and certain other molecules. Many of them are constitutively located within the nucleus, whereas others, such as the steroid hormone receptors, form complexes with heat shock proteins within the cytoplasm in the absence ligand, and then translocate into the nucleus upon hormone binding. Ligand-bound receptors bind to DNA response elements in the promoter region of target genes, whereupon they recruit coactivator proteins that have histone acetyltransferase activity to alter chromatin structure and enable RNA polymerase II binding. In addition to stimulating transcription of target genes, NRs can inhibit transcription both in the absence (basal repression) or presence of hormone (negative regulation). Many NRs, such as thyroid and steroid hormone receptors, bind endocrine hormones; however, other NRs [e.g., PPARs, FXRs, and liver X receptors (LXRs)] bind to intracellular ligands such as fatty acids, bile acids, and sterols, respectively. Additionally, there are some members (orphan receptors) that do not bind to any identified ligand; thus, they may function in a ligand-independent manner. The hormones that bind to NRs regulate a large number of diverse functions, such as growth, differentiation, reproduction, and metabolism, at both the physiological and cellular levels. Recently, there is emerging evidence that hormones for nuclear receptors can regulate autophagy in specific tissues under particular conditions; this evidence is summarized below.
TH
The THs, thyroxine and the more bioactive form, triiodothyronine (T 3 ), are iodine-containing tyrosinederived hormones that are critical for normal development, growth, and metabolism (141, 142). There are 2 major receptor isoforms, TH receptors a and b, which are expressed in variable amounts in virtually all tissues. The receptors belong to the NR superfamily, which is composed of receptors that act as ligand-inducible transcription factors. They are located primarily in the nucleus and bind to hormone response elements composed of specific DNA sequences in the promoter regions of target genes. Ligand-bound receptors regulate transcription through the recruitment of various coactivator and corepressor proteins to form transcriptional complexes that regulate transcription. The coactivator complexes increase transcription and generally contain enzymes that increase histone acetylation and methylation, ATP-dependent chromatin remodeling, or formation of mediatorlike complexes that can interact with RNA polymerase II in the promoter region near the DNAbound receptor. In the absence of TH, unliganded thyroid hormone receptor (TR) still binds to its hormone response element but recruits a different set of corepressor complexes that have histone deacetylase activity and induce chromatin in the local promoter region to form a more closed, repressed state. Of note, TH also can decrease transcription of some target genes; however, little is known about the precise mechanism(s) for the negative regulation of these genes. Besides TR-mediated effects on gene expression, TH also can have nongenomic effects that regulate cell signaling pathways (141, 142) .
In the liver, TH increases basal metabolic rate, lipid b-oxidation, and gluconeogenesis (143) . Interestingly, TH can stimulate both triglyceride synthesis (144) and fatty acid catabolism (145) . Most of these effects are transcriptionally regulated by TH (Fig. 3) . In the late 1970s, DeMartino and Goldberg (146) showed that TH increased the activity of lysosomal enzymes in skeletal muscle and liver, but not in heart or kidney. More recently, we observed that TH-induced autophagy of lipid from fat droplets in the liver (lipophagy) increases b-oxidation and oxidative phosphorylation (Fig. 3) (75) . Additionally, we found that autophagy was decreased in hypothyroid mice and increased in hyperthyroid mice. Furthermore, they were dependent upon TR expression, given that T 3 -stimulated autophagy was abrogated in dominant negative TRb mutant knockin mice (75) . The TH-mediated effects on autophagy were a result of increased AMPK-mediated phosphorylation and reduced mTOR-mediated phosphorylation of ULK1 to initiate phagophore formation (Fig. 3) . Recently, it was reported that increased expression of angiopoietinlike 8 protein by TH also might play a role in stimulating TH-dependent autophagy (147) .
Excessive TH-stimulated oxidative phosphorylation can lead to formation of mitochondrial reactive oxygen species (ROS) that can cause mitochondrial damage and cell death (148) . As a protective mechanism against accumulation of increased ROS-damaged mitochondria, TH was also found to stimulate the autophagy of mitochondria (mitophagy; Fig. 3 ) in hepatic cells and liver through a ROS/calcium/calmodulin-dependent protein kinase kinase b (CAMKKb)/AMPK-mediated pathway that was ROS-and ULK1-dependent (149). This THs also increase mitochondrial activity and transcription of mitochondrial genes directly by interacting with mitochondrial displacement loop. Increased mitochondrial activity by THs increases ROS generation. Increased ROS damages mitochondria, whereas it activates AMPK (via Ca 2+ signaling) and inhibits mTORC1 signaling. This activates ULK1, which, on the one hand, recognizes damaged mitochondria for mitophagy, and on the other hand, increases autophagosome formation and lipophagy. Concurrent increase in mitophagy, lipopahgy, and mitochondrial biogenesis helps to sustain increased mitochondrial activity, b-oxidation, and a healthy mitochondrial pool at the same time.
press.endocrine.org/journal/edrv 79 pathway appeared to be different than that required for general autophagy, because the latter could still occur in the absence of ULK1, most likely due to substitution by ULK2 activity, whereas mitophagy was prevented by loss of ULK1 expression. Interestingly, TH recruited the fission protein, drp1, as well as the autophagy proteins, ULK1, LC3, and SQSTM1/p62, to the biochemically separated mitochondrial fraction, suggesting that mitochondrial fission may be necessary for mitophagy to occur. Taken together, TH promoted a coordinated induction of both lipophagy and mitophagy to increase b-oxidation of fatty acids and remove ROS-damaged mitochondria (149) . Additionally, TH stimulated mitochondrial turnover in liver and muscle by stimulating peroxisome proliferatoractivated receptor gamma coactivator 1-alpha expression and mitochondrial biogenesis to replenish the mitochondrial pool with newly synthesized mitochondria ( Fig. 3 ) (149, 150) . The incidence of nonalcoholic fatty liver disease (NAFLD) is increased in patients with hypothyroidism; in addition, hypothyroidism is more common in patients with NAFLD (151) (152) (153) (154) (155) (156) (157) (158) (159) . At the genomic level, many of the genes that had altered expression in NAFLD were TH regulated (160) . Additionally, T 3 and TH analogs decreased hepatosteatosis in cell culture (75) and in rodent models (161) (162) (163) . Given that decreased autophagy leads to the development of fatty liver and insulin resistance (164), TH-mediated stimulation of lipophagy and b-oxidation of fatty acids support the notion that decreased intrahepatic TH concentration and/or signaling may be involved in hepatosteatosis and hepatic damage in NAFLD (165) . Apart from its effects on lipophagy and mitophagy, TH-induced autophagy also has been linked to increased cellular survival in ischemiareperfusion injury (166, 167) and in preventing protein aggregate formation (168) .
Vitamin D
Vitamin D helps regulate calcium and phosphate levels in the body and is critical for maintaining adequate bone mineral density by its effects on bone, gut, and kidney (169) . It also is important for maintenance of the innate immune system and may confer some protection against various cancers. The VDR is expressed in many tissues and likely has diverse effects; however, its precise function(s) in many tissues is not well understood.
Vitamin D induced autophagy in vascular endothelial cells that was associated with increased Beclin 1 and p-ERK expression (170-172). The upregulated Beclin 1 then bound to class III phosphoinositide 3-kinase to stimulate autophagy in macrophages and leukemic cells (171, 172) . In a mouse liver reperfusion injury model, vitamin D induced autophagy and cell protection through activation of ERK1/2 and inhibition of mTOR phosphorylation (173) . In contrast with these results, tissuespecific knockout of VDR reduced autophagy, altered the microbiome, and increased susceptibility to inflammation in an experimental mouse model of colitis (174, 175) . The loss of VDR in colon epithelial cells also decreased the expression of ATG16L and lysozyme as well as increased the risk for colitis in this model.
Steroid hormones
Most of the studies on autophagy have focused on steroid hormone effects on autophagy in steroid hormonesensitive cancers, such as prostate, breast, and uterine cancer. Currently, little is known about the roles of steroid hormones on autophagy under normal physiological conditions.
Androgens stimulate the development and growth of the normal prostate gland, and can further stimulate the growth and glucose metabolism in prostate cancer cells. Androgens may also promote cancer cell growth through induction of ROS-dependent autophagy (176) . In studies of prostate cancer cells, androgen removal or blockade caused intracellular energetic stress that led to activation of AMPK and autophagy to promote their survival (177-180). There also was increased formation of lipid droplets, lipophagy, and b-oxidation of fatty acids in the prostate cancer cells under these conditions (180) . Interestingly, androgenindependent prostate cancer cells had constitutively high levels of activated AMPK that could have enabled these cells to achieve androgen independence (180) .
The majority of breast cancers express estrogen receptor a (ERa), and they usually are initially sensitive to antiestrogen therapy. In breast cancers that were responsive to antiestrogens, induction of autophagy promoted cancer cell survival, although it was unable to overcome completely the cytotoxic effects of the antiestrogens (181, 182) . It also is possible that estrogen itself may prevent autophagy in some breast cancers, given that knockdown of ERa induced autophagy (181) . The effects of estrogen and progesterone also may be different in normal breast tissue than in breast cancers, because both hormones were able to stimulate autophagy during bovine mammary gland differentiation (183) .
Both estrogen and progesterone suppressed matingdependent autophagy in the uterus of ovariectomized mice (184) . The suppression was associated with glycogen accumulation in the uterus and suggested that autophagy may be a mechanism for glycogen breakdown during hormone withdrawal in the uterus (184) . In this regard, it appeared that autophagy was involved in the endometrial cell cycle, particularly during the late secretory phase. Autophagy commonly is a mechanism for drug resistance to chemotherapy, and it was observed that increased autophagy was associated with loss of responsiveness to antiestrogen therapy in breast cancer (181) .
There have only been a few studies of the effects of glucocorticoids on autophagy. Glucocorticoids stimulated the transcription of autophagy genes such as ATG5, LC3, Beclin 1, and SQSMT1/p62, as well as activated AMPK to promote muscle atrophy (185) . Low doses of glucocorticoids also stimulated autophagy in osteoclast, osteocytes (186) (187) (188) (189) , and in leukemic cells (190, 191) , but the intracellular roles of this autophagy have not been well characterized.
PPAR/FXR/LXR ligands
PPARa and the bile acid receptor, FXR, are activated by intracellular ligands such as essential fatty acids and bile acids, respectively. These ligands are generated within the cell, reflect the internal energy and nutrient states of the cell, and may be thought of as "intracrine" hormones (192) . Recently, it was shown that PPARa and FXR regulate autophagy genes in the liver in a reciprocal manner during different nutrient conditions (70) . After starvation, when lipophagy and b-oxidation of fatty acids were normally stimulated, FXR suppressed autophagy. In contrast, during the fed state, autophagy was suppressed, but activation of PPARa stimulated lipophagy. This crossregulation of autophagy was mediated by transcriptional regulation of autophagy genes by these 2 NRs. In a similar manner, CREB promoted autophagy during the fasted state, whereas FXR ligands inhibited this effect (72) . These reciprocal pathways involving FXR with PPARa and CREB enable the liver to regulate autophagy and b-oxidation of fatty acids appropriately during the fed and fasting states. On the other hand, FXR still may be needed for autophagy response to ethanol exposure, given that FXR knockout mice had impaired FOXO3a-mediated autophagy and were more susceptible to alcohol-induced injury (193) . Similarly, gut microbial metabolites have been shown to regulate autophagy via PPARg (194) . Moreover, there is little information about the effects of LXRs on autophagy. These receptors are activated by sterols and stimulate the transcription of target genes involved in lipogenesis. Interestingly, the lipogenic program normally activated by LXR was impaired in autophagy-defective mice that lacked FIP200 in their livers (195) , as well as in hepatocytes lacking ULK1 expression (196) .
Ghrelin and growth hormone
Ghrelin is a hormone produced by the gut that also stimulates growth hormone secretion (197) . It is a potent stimulator of appetite and also directly acts on peripheral tissue to increase lipolysis and increase blood glucose levels. Growth hormone is a polypeptide secreted by the pituitary that promotes growth during childhood. It also has important metabolic functions by serving as a counterregulatory hormone during hypoglycemia (198) . In fasted, fat-depleted mice that lacked functional ghrelin and growth hormone, growth hormone treatment before and during fasting protected them from fatal hypoglycemia (175) . This protection was associated with a large increase in hepatic autophagy that did not occur in the control mice lacking growth hormone (175) . Ghrelin treatment also directly induced autophagy in cultured cardiomyocyte cell lines (199) , as well as in liver, where it protected against hepatosteatosis in mice fed a high-fat diet (200) . (129) myokines (202, 203) Ghrelin (194) Leptin (200) Adiponectin (198) Myokines (203) Leptin (200) Abbreviations: BAT, brown adipose tissue; GLP-1, glucagon-like peptide-1; WAT, white adipose tissue. Adiponectin is a peptide hormone secreted by white adipose tissue that promotes AMPK activation and lipid catabolism in target tissues (201) . Adiponectin promoted induction of autophagy and survival of colon cancer cells during glucose starvation (202) . Lack of adiponectin in knockout mice fed a high-fat diet led to further repression of myocardial autophagy, increased cardiac hypertrophy, and increased metabolic derangements (203) . In contrast, when adiponectin knockout mice were fed a high-fat diet and given adiponectin replacement, there was restoration of autophagy in skeletal muscle (204) .
Leptin is another hormone secreted by white adipose tissue that serves as a signal for satiety. In leptin knockout models, increased autophagy was observed in muscle, liver, and heart (205) ( Table 1 ). Enteric feeding of leptin decreased autophagy in the gut (206) ; however, infusion of leptin in vivo paradoxically increased autophagy in most tissues, and the direct treatment of muscle cells also increased autophagy (205) . These findings suggest that there may differences between neuroendocrinemediated and tissue-autonomous effects of leptin on autophagy.
Myonectin is a myokine that is secreted in the fed state. It repressed autophagy in the liver even during starvation (207) . These effects were mTOR mediated, given that inhibition of mTOR activity abrogated these effects in cultured hepatic cells (207) . The potent effects of the myokine, fibroblast growth factor 21 (FGF21), on overall metabolism was demonstrated in the muscle-specific knockout Atg7 mice (208) , which surprisingly were lean as well as protected from diet-induced obesity and insulin resistance (208) . These mice also exhibited increased browning of white adipose tissue and increased fatty acid b-oxidation in the liver. These unexpected findings were eventually explained when it was shown that autophagy deficiency and mitochondrial dysfunction in the muscle led to increased production of the myokine, FGF21, which in turn provided protection against obesity and insulin resistance. Although FGF21 appears to be a potent stimulator of b-oxidation in the liver, so far, there have not been any reports on its effects on autophagy.
IV. Role of Autophagy in Endocrine and Metabolic Disorders
Diabetes
Autophagic regulation of insulin secretion from pancreatic b-cells
Crinophagy represents a major pathway for degrading insulin granules in b-cells (209) . Crinophagic activity is dependent upon ambient glucose levels. At low glucose levels, crinophogy increases, whereas intracellular insulin levels decrease. In contrast, at high glucose levels, insulin degradation is inhibited to maximize insulin secretion (31, 210). Besides glucose, hormones such as corticosterone and progesterone can alter intracellular degradation of insulin by binding to the glucocorticoid receptor and perturb the production of prostaglandins within the b-cells (211) . Recently, Goginashvili et al. (212) described a form of crinophagy in which which insulin-containing granules are preferentially degraded by lysosomes at low extracellular glucose concentrations. This process, termed by the authors as starvation-induced nascent granule degradation, was regulated by protein kinase D and MTORC1 activity and described as a unique way for b-cells to cope with starvation. In contrast, insulin secretion was increased by induction of autophagy and inhibition of crinophagy. Currently, the roles of crinophagy and autophagy in insulin granule degradation and secretion still remain controversial. In contrast to the studies by Goginashvili et al. (212) , several other studies showed that autophagy negatively regulated insulin secretion and increased insulin degradation (213) (214) (215) . These differences will need to be resolved in the future; in addition, the roles of crinophagy and autophagy in the secretion of other pancreatic endocrine hormones will need to be determined.
Autophagy and control of b-cell survival under stress
Support for a prosurvival role for autophagy came from studies on b-cell-specific knockout of Atg7 in mice (216, 217) . These studies clearly showed that autophagy deficiency in b-cells led to decreased tolerance to stress. The autophagy-deficient b-cells accumulated intracellular protein aggregates and dysfunctional mitochondria and displayed impaired glucose-stimulated insulin release. Additionally, increased b-cell death due to lipotoxicity was also linked to impaired autophagy (218) . The upregulation of ER stress in b-cells due to the increased demand for insulin production in diabetes also has been associated with decreased autophagy. Thus, induction of autophagy appears to be beneficial to b-cells by relieving ER stress and proteotoxicity from aggregates in diabetes (219) (220) (221) (222) (223) (224) (225) . Similarly, autophagy may be helpful in preventing oxidative damage to b-cells in diabetes (226) . Impaired autophagy also can cause islet b-cell damage through the accumulation of human islet amyloid polypeptide (hIAPP) (227) (228) (229) . In this regard, treatment of b-cells with hIAPP increased autophagic flux, whereas inhibition of autophagy increased the cytotoxic effects of hIAPP. Furthermore, double b-cell-specific autophagy knockout and hIAPP knockin mice had impaired glucose tolerance (227) (228) (229) . Apart from general autophagy, mitophagy deregulation has also been implicated in b-cell dysfunction during the progression of diabetes (230-234).
Autophagy and its role in peripheral insulin sensitivity
Autophagy appears to play a key role in both glucose utilization and the development of insulin resistance in skeletal myocytes. Exercise increased glucose utilization and induced autophagy in mouse skeletal muscle (235, 236) . Similar effects of exercise on muscle autophagy (237) (238) (239) (240) (241) (242) (243) and insulin sensitivity (244) also have been reported in humans. Mice with deficient exercise-induced autophagy demonstrated reduced insulin sensitivity and decreased glucose utilization during strenuous exercise, with concomitant impairment of plasma membrane expression of the glucose transporter 4 and impaired glucose tolerance in mice fed a high-fat diet. These results suggest that skeletal muscle autophagy is an important driver of glucose tolerance in diabetes and obesity (235) . Similar to skeletal muscle, downregulation of hepatic autophagy was shown to increase insulin resistance in diet-induced obesity models in mice (164) . Moreover, hyperinsulinemia secondary to insulin resistance further impaired hepatic autophagy by downregulating FOXO1-mediated autophagy (245) .
Adipose tissue is another key target of insulin action, and impaired autophagy in this tissue has been investigated in relation to diabetes (246) . Autophagy also played a critical role in the differentiation of white vs brown adipocytes (131, (247) (248) (249) (250) (251) (252) . Interestingly, unlike its effect on liver and muscle, decreased autophagy in the adipose tissue of mice reduced body fat due to impaired differentiation into white adipose tissue. These mice also had browning of white adipose tissue leading to increased fatty acid oxidation, improved insulin sensitivity, and glucose utilization (131, 252) . However, the selective effects of autophagy in white vs brown adipose tissue on insulin sensitivity and glucose tolerance are not well understood. Of note, adipocytes from patients with type 2 diabetes had increased autophagy (253) (254) (255) ; however, it is not known whether this increased autophagy was a cause or consequence of diabetes and/or insulin resistance.
Autophagy in diabetes-associated inflammatory signaling
Tissue inflammation is 1 of the key mechanisms underlying the development of insulin resistance in obesity (256) . Inflammasome activation in macrophages via the NLR family pyrin domain containing 3 receptor played an important part in the development of type 2 diabetes mellitus in animal models and human patients (257) . Selective autophagy decreased inflammasome activity by removing dysfunctional mitochondria and eliminating active inflammasome complexes (258) . Obesity or administration of saturated free fatty acids resulted in NLR family pyrin domain-containing 3-mediated hyperactivation of the inflammasome and oversecretion of the cytokine interleukin 1 (IL-1) b in macrophages, which in turn led to impairment of insulin signaling in peripheral tissues. Although global haplodeficiency of Atg7 in obese mice caused insulin resistance with concomitant increases in lipid-associated inflammation and maturation of pro-IL-1b to IL-1b (259), downregulation of macrophage autophagy by both acute and chronic inflammatory stimuli also led to release of proinflamatory cytokines (260, 261) . Notably, macrophage-specific Atg7 knockout mice displayed a shift in the proportion to proinflammatory M1 macrophages and exhibited impaired insulin sensitivity and glucose homeostasis when fed a high-fat diet (260) .
Autophagy in diabetes-associated complications
Diabetic nephropathy (DN) is one of the major complications of diabetes and remains the leading cause of latestage kidney failure in the world. DN is characterized by podocyte injury, thickening of glomerular basement membrane, mesangial expansion, and proteinuria. The autophagy/lysosomal pathway plays an essential role in maintaining podocyte function, and a high rate of autophagic flux occurs in these cells (262) . Autophagy deficiency led to glomerular lesions accompanied by podocyte loss and increased albuminuria (263) . Recent studies also suggested an important role of autophagy in promoting podocyte health and the progression to DN (264) (265) (266) (267) (268) (269) . Similar to podocytes, experimental models with loss of autophagy in the proximal tubular cells also showed progressive renal failure (270) (271) (272) (273) (274) (275) . Apart from DN, diabetic cardiomyopathy was associated with the inhibition of general as well as selective autophagic flux (59, 276-282). However, opposite effects of type I and type II diabetes on cardiac autophagy have been reported in mice (277) .
Obesity
Role of autophagy in adipose tissue differentiation
Several lines of evidence support the notion that autophagy plays an important role in adipose tissue differentiation. Reduced adipogenesis was observed in mouse embryonic fibroblasts derived from Atg5 2/2 (autophagy deficient) mice and other ATG-deficient preadipocyte cells grown in culture (283, 284) . Consistently, adipogenesis also was impaired in mice lacking ATG7 (131, 251, 252) , given that they had smaller white adipose tissue depots, suggestive of a defect in adipocyte differentiation. Also, adipocyte-specific knockdown of ATG7 resulted in the development of adipose tissue that phenotypically and functionally resembled brown fat (browning of white fat cells), containing multiloculated adipocytes and abundant mitochondria, indicative of increased oxidative capacity (131, 251, 252) . Although the general mechanism by which autophagy regulates adipocyte differentiation is not fully understood, it is thought that selective loss of organelles, especially mitochondria, may favor the development of doi: 10.1210/er.2016-1103 press.endocrine.org/journal/edrvwhite adipose tissue during adipogenesis (248) . In addition, autophagy was reported to prevent degradation of PPARg2, a master regulator of adipocyte differentiation and adipogenesis (285), as well as lower the protein levels of several negative regulators of adipogenesis, such as Krupple-like factors klf2 and klf3 (249) . Intriguingly, impaired adipogenesis also was observed in animal models with defective autophagy in other tissues, such as muscle (286) , suggesting interorgan crosstalk may support adipocyte development and differentiation.
Role of autophagy in adipocyte lipolysis
Although lipolysis in adipose tissue is mostly regulated by classical lipases such as hormone-sensitive lipase and adipose triglyceride lipase, recent studies suggest that autophagy may be involved in the adrenergic-mediated lipolysis pathway in white adipose tissue (130) . This autophagic process is called lipophagy and involves degradation of lipids by lysosomal lipase. FOXOs comprise a family of transcription factors that stimulate genes encoding ATG proteins and are negatively regulated by insulin. During insulin resistance, FOXOs are activated and stimulate lipophagy and lipolysis in white adipose tissue (287) . Similar to the adrenergic stimulation of white adipose tissue, a recent study showed that cold temperature induced autophagy in proopiomelanocortin (POMC) neurons in the hypothalamus and activated lipophagy in brown adipose tissue via sympathetic stimulation in mice. Interestingly, the autophagic machinery also was found to be coupled to the classical lipases to increase lipolysis (288) . Thus, both cellautonomous as well as central regulation of autophagy play important roles in adipose tissue lipolysis.
Autophagy regulation of adipocytes in obesity
Human studies have shown that autophagosome number is increased in isolated adipocytes derived from obese and diabetic humans (253) . These findings were confirmed by others using whole adipose tissue derived from omentum or subcutaneous depots of obese patients undergoing bariatric surgery (289) (290) (291) (292) . Studies in humans have shown that transcriptional upregulation of adipose tissue autophagy genes in obesity was mediated by the transcriptional activity of E2F1 (255) . The key role for E2F1 in the transcriptional regulation of adipocyte autophagy was demonstrated by showing E2F1-dependent induction of ATG mRNA and protein expression levels, and autophagic flux (255) . Other transcriptional regulators of adipocyte autophagy in obesity are the FOXO transcription factors. Because FOXO transcription factors are negatively regulated by insulin, insulin resistance associated with obesity may explain the upregulation of autophagy in adipose tissue of humans (287) . Other possible causes of increased autophagy also have been ascribed to increased ER stress in adipose tissue as a result of excessive lipid accumulation that also regulated the secretion of adiponectin (293) . Interestingly, upregulated autophagy in adipocytes may also downregulate IRs and worsen insulin resistance (294) . In contrast to white adipose tissue, chronically increased autophagy negatively impacted brown adipose tissue activity (295) , which was rescued by autophagy impairment in mice (296) . Besides adipocytes, adipose tissue macrophages also had dysfunctional autophagy in obesity, leading to their differentiation into a more proinflammatory phenotype (260, 261) .
Autophagy in hypothalamic regulation of obesity
The role of autophagy in central control of whole body energy balance has been a topic of recent research interest. Autophagy gene (Atg7) knockdown in the hypothalamus of mice resulted in weight gain (297) . The expression of inflammatory markers also was increased in the hypothalamus of these mice, and a neuron-specific deletion of I kappaB kinase b rescued the metabolic phenotypes in these mice, suggesting a role for inflammation in obesity associated with hypothalamic autophagy deficiency (297) . Further studies revealed that autophagy in different neuronal populations of the hypothalamus had opposite effects on energy metabolism. Mice with Atg7 specifically deleted in agouti-related peptide (AgRP) neurons that produce orexigenic hormones, such as AgRP and neuropeptide Y, displayed a lean phenotype, which was attributed to failure of these neurons to induce expression of AgRP in response to free fatty acids released during starvation (298) . Furthermore, these mice expressed increased levels of the anorexigenic hormones, POMC and a-melanocyte-stimulating hormone (298) . In contrast, Atg7 deletion in POMC neurons (Atg7DPOMC) that produced anorexigenic hormones such as a-melanocyte-stimulating hormone had an obese phenotype (299, 300) . These results were due to increased fat mass caused by excessive food intake and reduced energy expenditure. Atg7DPOMC male mice also displayed glucose intolerance and elevated nonfasting glucose levels after a high-fat diet (299) (300) (301) . Furthermore, activation of signal transducer and activator of transcription 3 and suppression of food intake during refeeding after prolonged fasting by leptin was reduced in Atg7-deficient POMC mice compared with wild-type mice, suggesting that autophagy-deficient POMC neurons were resistant to leptin (299, 301) . Taken together, these results suggested that the metabolic influence of hypothalamic autophagy was highly dependent upon the neuron type.
Autophagy in obesity-associated cardiac complications
Central obesity and dyslipidemia, associated with elevated levels of lipids in the blood, predisposes individuals to the development of cardiovascular disease, such as atherosclerosis. Autophagy has been shown to play a major role in the development and pathogenesis of atherosclerosis (302) . Impairment of autophagy in circulating monocytes/macrophages increased inflammatory cytokine production and inflammosome activation within atherosclerotic lesions (303, 304) . Also, macrophage autophagy and lysosomal lipase activity mediated cholesterol efflux, prevented cytosolic lipid accumulation, and suppressed macrophage foam cell formation to decrease the progression of atherosclerosis (305) .
NAFLD and nonalcoholic steatohepatitis
NAFLD is commonly associated with both obesity and diabetes. The disease itself is composed of different stages of progressive pathologies ranging from benign accumulation of fat in the liver to a more severe form known as nonalcoholic steatohepatitis (NASH). This stage of NAFLD is characterized by increased hepatocyte inflammation and necrosis and can eventually progress to liver fibrosis and cirrhosis. Autophagy plays a distinct and critical role in NAFLD, as described below.
Regulation of autophagy in NAFLD
One key consistent finding in both animal and human studies on NAFLD was downregulation of hepatic autophagy (306) (307) (308) (309) (310) . Similarly, high-fat diet-induced obesity and genetic models of obesity showed decreased macroautophagy (100, 164) and CMA (311) in the liver. Additionally, mice and dogs with glucose-6-phosphatase deficiency developed glucose-6-phosphate excess and NAFLD as well as decreased autophagy (312) . Several mechanisms for the inhibition of autophagy in fatty liver have been proposed, including decreased expression of autophagy genes (245) , reduced calpain-mediated autophagy protein cleavage (313) , hyperactivation of MTORC1 (314) , and defective lysosomal acidification and/or autophagosome-lysosome fusion (315, 316) . Hyperinsulinemia as a result of insulin resistance also likely contributes to the hepatic defect in autophagy and initiates a selfperpetuating cycle in which hepatic lipid accumulation promotes insulin resistance, and both of these events impair autophagy, further worsening steatosis and insulin insensitivity in NAFLD (245) .
Lipophagy and its role in hepatic lipid metabolism
The key initial finding that prompted interest in the involvement of autophagy in NAFLD was the observation that autophagy mediated hepatic metabolism of intracellular lipids (100) . In this study, both pharmacological inhibition of autophagy and genetic knockdown of the autophagy gene Atg5 increased lipid content in cultured hepatocytes after fatty acid supplementation.
Furthermore, electron micrograph images showed decreased lipid trafficking in autophagosomal-lysosomal compartments. Thus, the inhibition of autophagy or lipophagy decreased the catabolism of triglycerides stored in lipid droplets, leading to increased steatosis after a lipid challenge. More importantly, lipophagy was physiologically coupled with mitochondrial fat oxidation. Lipophagy as a mechanism of lipid catabolism in mammalian liver also has been shown to be regulated by several hormone receptors and naturally occurring compounds (70, 75, 129, 143, 315, 317, 318) . Taken together, these findings have identified an essential function for autophagy in the regulation and metabolism of hepatic lipid stores, and suggest that impairment in this pathway could be a mechanism for the development of hepatic steatosis. Alternative mechanisms by which autophagy may regulate hepatocyte lipid metabolism have been described for CMA. Mice with an inhibition of CMA as a result of a knockout of LAMP-2A developed hepatic steatosis in association with abnormalities in carbohydrate and lipid overload due to failure to degrade certain metabolic enzymes by CMA (319) . CMA also was shown to target specifically 2 critical lipid droplet proteins, perilipin 2 and perilipin 3, that inhibit both classical lipase and macroautophagy-mediated lipolysis (320) . The degradation of these 2 proteins promoted both enzymatic and lipophagy-mediated lipolysis.
In contrast with the previous studies, others have reported decreased steatosis when hepatocyte autophagy was inhibited (195, 321, 322) . The inconsistences observed among different groups may be due, in part, to different genetic models, dietary conditions, levels of autophagy inhibition, the autophagy-independent action of some autophagy proteins, or other experimental conditions in the studies. Therefore, although considerable evidence supports the notion that reduced hepatocyte autophagy promotes hepatosteatosis, controversy still remains, and further research is needed. Additionally, the role and clinical significance of autophagy in patients with NAFLD needs to be elucidated.
Role of autophagy in hepatic lipotoxicity
The disease progression from benign steatosis to steatohepatitis (NASH) is associated with death receptor pathway activation, mitochondrial damage, endoplasmic reticulum stress, reactive oxygen species formation, and activation of inflammatory pathways (e.g., c-Jun N-terminal kinase, Ikk/nuclear factor kB, and toll-like receptor 4) by toxic lipid metabolites such as diacylglycerols and ceramides (323) . These toxic metabolites in the liver are readily generated from saturated fatty acids, such as palmitate, and cause mitochondrial dysfunction, caspase activation, and apoptosis (324) . Autophagy has been doi: 10.1210/er.2016-1103 press.endocrine.org/journal/edrvshown to protect against saturated fatty acid/death receptor-mediated apoptosis from both tumor necrosis factor and Fas, 2 factors that have been implicated in hepatocellular injury in NASH (325) (326) (327) . Autophagy was also reported to protect against cell death from ER stress (309) in NASH ( Table 2 ).
V. Autophagy and Endocrine-Related Cancers
Autophagy in endocrine tumors
Some of the earliest accounts of autophagy deregulation in endocrine tumors were reported in pituitary adenomas, in which increased upregulation of autophagy and crinophagy was associated with an increase in intracellular degradation of secretory granules. This deregulation of autophagy prevented adrenocorticotrophin secretion in so-called silent adenomas (328) . Similarly, in a case study of a patient with acromegaly and inappropriate serum growth hormone levels, the patient had increased crinophagy-mediated degradation of growth hormone in the pituitary tumor (329) .
Examples of autophagy in response to therapy also have been documented for several endocrine malignancies (330) . Paradoxically, autophagy seemed to promote both cancer cell survival and cell death (331), depending upon the specific context. It has been suggested that the role of autophagy varies depending on the stage of tumor development, given that autophagy limits tumor formation in the early stages, whereas it favors tumor cell survival and invasion in later stages (332) . Autophagy also regulated carcinogenesis in a cell-and tissue-specific manner (333) , and its ultimate influence on cell survival vs cell death may depend on the type and strength of stress experienced by a cancer cell when challenged with a chemotherapeutic agent. Enhancement of tumor cell survival by drug-induced autophagy has been observed in adrenal (334) and thyroid cancers (335, 336) . Interestingly, induction of crinophagy by drugs such as acrylonitrile and SMS 201-995 increased the degradation of growth hormone in pituitary adenoma somatotropes (337, 338) . Other aspects of autophagic signaling in cancers, such as so-called autophagic cell death, have been a topic of intense research and have been well described (339) .
Hormonal regulation of cancer cell autophagy
Endocrine-related cancers, namely breast, endometrium, ovary, prostate, testis, thyroid, and osteosarcoma, share common mechanisms for carcinogenesis (340) . Both peptide and steroid hormones may promote tumor growth by stimulating cell proliferation or decreasing tumor-suppressor activity to increase genomic instability and the likelihood for random genetic errors. An important feature of tumor development is the relative inability of cancer cells to undergo apoptosis. In this regard, cytokines and growth factors may play important roles as stimulators for survival. Additionally, the overexpression of their receptors (e.g., IGF-1R, IGF-2R, and IR) can be important contributing factors. The first suggestions that autophagy may suppress tumor growth were the obervations that it was frequently downregulated in tumor cells (341) , and that low levels of autophagy were associated with tumor progression (342) . Of note, the class I phosphoinositide 3-kinase pathway often was activated in cancer cells, resulting in induction of antiautophagic AKT and mTORC1 signaling. In this regard, members of the IGF family and other growth factors, particularly those with tyrosine kinase activity, have been implicated in decreasing autophagy and promoting tumor growth (343) .
Likewise, exposure to estrogens is 1 of the most common risk factors for breast cancer. Interestingly, the antiestrogen drug, tamoxifen, increased cell death in mammary carcinoma cells via an autophagy-mediated 
VI. Novel Therapeutic Approaches to Target Autophagy in Endocrine and Metabolic Disorders
Autophagy modulation recently has gained importance in the field of endocrinology and metabolism. Although many of the known proautophagic drugs were not originally designed or developed to induce autophagy, some of their beneficial effects may be mediated via autophagy regulation. The general classes of autophagy modulators affecting different steps of autophagy signaling in metabolic disorders can be characterized as follows.
mTORC1 inhibitors and rapalogs
MTORC1 is a master negative regulator of autophagy, and its inhibition has been used to initiate autophagy in mammalian cells. In this regard, the classical MTORC1 inhibitor, rapamycin, has shown promising results in several preclinical studies on treating metabolic diseases. Rapamycin treatment has shown efficacy in reducing DN in streptozotocin-treated animals (312, 359, 360) . This protection was accompanied by reductions in glomerular a-smooth muscle actin expression, mesangial matrix accumulation, and renal hypertrophy in streptozotocin-induced diabetes. There also was reduced expression of several proproliferative cytokines and monocyte chemo-attractant protein-1 (361) . Similar effects were also observed with MTORC1 inhibition in DN models using db/db mice (362) . Unfortunately, chronic rapamycin treatment is associated with insulin resistance and hyperglycemia in animals and humans (363) . The induction of diabetes by rapamycin mimics "starvation diabetes" and may not necessarily be pathological (364) . Nonetheless, the use of rapamycin for diabetes management is still under investigation and remains controversial owing to its potential side effects. There have been favorable results for the use of MTORC1 inhibitors to induce autophagy in NAFLD.
Rapamycin showed beneficial effects in reducing hepatic steatosis in several animal models of NAFLD and NASH by increasing autophagy (365) (366) (367) . Other MTORC1 inhibitors, such as caffeine, also showed similar positive effects on liver fat clearance via autophagy (318) .
AMPK/SirT1 activators
AMPK is a nutrient-sensing kinase which is activated under energy-depleted conditions and is, in contrast to the mTORC1 pathway, a positive regulator of autophagy. Several hormones, natural compounds, and drugs that induce AMPK activity have increased islet b-cell survival (368) (369) (370) and protected against diabetic complications (236, 276, 281, (371) (372) (373) (374) (375) (376) (377) (378) (379) . AMPK activators also showed beneficial effects in reducing lipid accumulation in nonadipose tissues by inducing autophagy in animal models of obesity (101, 317, 377, 380) . Similar to the direct AMPK activators, SirT1 activators also exhibited beneficial metabolic outcomes by activating AMPK and inducing autophagy (280, (381) (382) (383) (384) (385) . In this regard, both resveratrol as well as metformin protected against diet-induced NAFLD and tissue injury (280, 381, 386, 387) .
Other strategies to modulate autophagy in metabolic disorders
Recently, calcium channel blockers were shown to prevent the pathological manifestations of NAFLD and NASH (315, 388) . The rationale for their use was restoration of autophagy that was blocked by induction of hepatic calcium flux during obesity. This increase in intracellular calcium concentration inhibited autophagosome-lysosome fusion and autophagic flux. Interestingly, impairment of autophagosomal-lysosomal dynamics also has been implicated in several lysosomal storage diseases (389) . In this regard, inducing autophagic flux by increasing the activity of TFEB (transcriptional master regulator of autophagylysosomal genes) has shown promising beneficial effects (390) . Recently, several small molecule activators of TFEB were discovered that may be potentially effective in the treatment of genetic and metabolic diseases that have impairments in autophagy (391) . Tat-beclin-1 peptide represents a highly specific and targeted proautophagy inducer that has potential efficacy in the treatment of autophagic defects in human diseases (392).
VII. Future of Autophagy Research in Endocrinology/Metabolism
The study of hormone regulation of autophagy is still in its infancy, despite the early observations by De Duve over 50 years ago. In cancer, autophagy seems to promote cell survival and chemotherapy resistance. In contrast, in cell metabolism, autophagy often is involved in fuel press.endocrine.org/journal/edrv 87 breakdown (lipid and glycogen), as well as in removal of damaged mitochondria, frequently due to ROS production from oxidative phosphorylation. The removal of mitochondria, mitophagy, is tightly coordinated with mitochondrial biogenesis in many tissues. Indeed, mitochondrial turnover, and its regulation by hormones and intracellular nutrient substrates and energy state, ultimately determines the quality of the mitochondrial pool in target tissues. This in turn may be affected by aging, obesity, nutrition, and endocrine function. Thus, improving mitochondrial function through mitophagy offers the potential for better metabolic function of tissues, improved hormone sensitivity, reduced ROS damage and oxidative stress, as well as restoration and regeneration of tissue function. Because autophagy is often increased in cancer, autophagy inhibitors have been proposed as therapeutic adjuncts. However, in endocrine and metabolic disorders, autophagy usually is impaired, either in the endocrine gland or the target tissues. So far, only autophagy inhibitors have been evaluated for cancer treatment in clinical trials; however, further work is needed to develop highly specific and less toxic autophagy inducers for clinical use in metabolic diseases (393) . In endocrine glands such as the pituitary or pancreatic islets, deficiencies in autophagy may lead to decreased polypeptide hormone secretion and their increased degradation by crinophagy. In target tissues such as fat, heart, muscle, and liver, impaired autophagy can lead to abnormal lipolysis or decreased b-oxidation of fatty acids. Additionally, autophagy can protect against glucotoxicity, lipotoxicity, and ROS damage in the cell. Over time, these defects often lead to insulin resistance, inflammation, and secondary damage in target tissues. Thus, understanding autophagy in both endocrine glands and their target tissues may lead to novel therapeutic approaches to increase hormone secretion as well as enhance sensitivity to hormones and tissue viability. For example, it is possible that autophagy induction, either by hormones or pharmacologically, may lead to increased secretion of insulin from islet b-cells or confer protection against lipotoxicity, glucotoxicity, or inflammation to increase their viability (394) . Likewise, increasing lipophagy and mitophagy in the liver could lead to decreased hepatosteatosis in NAFLD and lysosomal storage diseases (326) . Indeed, a number of hormone and drug therapies have shown initial promise for this condition (365, 395, 396) . Thus, harnessing the beneficial powers of autophagy in the endocrine system (Table 2 ) and targeting them to appropriate tissues to improve hormone secretion, hormone sensitivity, and/or intracellular metabolism will be exciting challenges that hold great promise for the future. press.endocrine.org/journal/edrv
